CIQ

CIQ is a GluN2C/GluN2D subunit-selective NMDA receptor potentiator, which reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. The facilitation of GluN2C/GluN2D-containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia.

Product information

CAS Number: 486427-17-2

Molecular Weight: 467.94

Formula: C26H26ClNO5

Synonym:

F0535-0139

SR-01000568996-1

J-690307

SR-01000568996

FT-0700317

HY-18699

DA-42329

NCGC00370786-06

MCULE-2981665299

CS-4969

CCG-222558

AKOS021662959

AKOS002095855

BDBM50436060

BCP14821

EX-A588

AOB5251

SCHEMBL7895807

Oprea1_287445

(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone

(3-chlorophenyl)-[6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]methanone

CHEMBL2397100

(3-chlorophenyl)[3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]methanone

(3-chlorophenyl)-[(1R)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]me

(3-Chlorophenyl) [3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]methanone

(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1 h)-yl)methanone

(3-Chlorophenyl)[3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]-methanone

2-(3-chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline

Chemical Name: (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone

Smiles: COC1C=CC(=CC=1)OCC1C2=CC(OC)=C(C=C2CCN1C(=O)C1=CC(Cl)=CC=C1)OC

InChiKey: VYMILMYEENZHAR-UHFFFAOYSA-N

InChi: InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-22-15-25(32-3)24(31-2)14-17(22)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

1. Kratz AL, Chadd E, Jensen MP, Kehn M, Kroll T. An examination of the psychometric properties of the community integration questionnaire (CIQ) in spinal cord injury. J Spinal Cord Med. 2014 Jan 3. [Epub ahead of print] PubMed PMID: 24621050.
2. Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, Stairs DJ, Dravid SM. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol. 2014 Feb;171(3):799-809. doi: 10.1111/bph.12518. PubMed PMID: 24236947; PubMed Central PMCID: PMC3969090.
3. Gontkovsky ST, Russum P, Stokic DS. Comparison of the CIQ and CHART Short Form in assessing community integration in individuals with chronic spinal cord injury: a pilot study. NeuroRehabilitation. 2009;24(2):185-92. doi: 10.3233/NRE-2009-0467. PubMed PMID: 19339757.
4. Kuipers P, Kendall M, Fleming J, Tate R. Comparison of the Sydney Psychosocial Reintegration Scale (SPRS) with the Community Integration Questionnaire (CIQ): psychometric properties. Brain Inj. 2004 Feb;18(2):161-77. PubMed PMID: 14660228.
5. Seale GS, Caroselli JS, High WM Jr, Becker CL, Neese LE, Scheibel R. Use of community integration questionnaire (CIQ) to characterize changes in functioning for individuals with traumatic brain injury who participated in a post-acute rehabilitation programme. Brain Inj. 2002 Nov;16(11):955-67. PubMed PMID: 12455520.

Products are for research use only. Not for human use.